Gastrointestinal Cancer

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Vincent Picozzi, MD, discusses how data from the phase 3 PANOVA-3 trial are foundational for the evaluation of Optune Pax with other immunotherapies.

The FDA has tentatively approved the abbreviated new drug application for the lutetium lu 177 dotatate radioequivalent PNT2003 in SSTR-positive GEP-NETs.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

February brought key GI cancer updates: FDA approvals in BRAF+ mCRC and pancreatic cancer, plus new fast track and orphan designations.

Obrixtamig plus platinum chemo showed a 72% response rate and manageable safety in frontline DLL3-positive NEC in the phase 1 DAREON-7 trial.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

The portable, noninvasive device has been approved for concomitant use with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

Manish A. Shah, MD, and Raji Shameem, MD, discuss potentially paradigm-shifting results from the HERIZON-GEA-01 study.

Manish A. Shah, MD, discusses the PFS benefit with zanidatamab plus chemotherapy with/without tislelizumab in HER2-positive GEA regardless of PD-L1 status.

EMA CHMP recommends first-line retifanlimab plus carboplatin/paclitaxel for advanced anal cancer, backed by phase 3 P0D1UM-303 data.

The FDA issued a reminder to increase awareness regarding updated capecitabine and 5-FU labels to highlight DPD deficiency risks.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

William A. Hall, MD, discusses the rationale of the phase 2/3 Janus Rectal Cancer Trial.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

An NDA for lirafugratinib in the second line for patients with FGFR2-altered cholangiocarcinoma has been submitted to the FDA.

An NDA for rivoceranib plus camrelizumab in frontline HCC has been resubmitted to the FDA, following the company's receipt of 2 CRLs for this indication.

The gremlin-1–directed monoclonal antibody ginisortamab showed early efficacy signals when combined with SOC therapy in patients with advanced GI tumors.

The novel oral fascin inhibitor NP-G2-044 received FDA orphan drug designation for patients with pancreatic cancer.

William A. Hall, MD, discusses the need for more precise radiation therapy in rectal cancer.

In an OncLive Peer Exchange, experts convened to discuss notable updates in pancreatic cancer from ASCO GI and beyond.

Raji Shameem, MD, discusses the significance of data from the phase 2 ILUSTRO trial of biomarker-guided triplet therapy in gastric and GEJ adenocarcinoma.

William A. Hall, MD, discusses remaining clinical questions in the field of rectal cancer.